{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:05:30Z","timestamp":1780538730632,"version":"3.54.1"},"reference-count":31,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background\/Objectives: L-carnitine and Coenzyme Q10 (CoQ10) are widely used in health and sports supplementation settings to improve energy metabolism, reduce fatigue, and support recovery. Although generally perceived as safe, their safety profiles are mainly based on pre-marketing studies and selected clinical populations, while real-world pharmacovigilance evidence remains limited. This study aimed to evaluate and compare the adverse drug reaction (ADR) reporting patterns associated with L-carnitine and CoQ10 using the EudraVigilance database. Methods: A retrospective pharmacovigilance analysis was conducted using spontaneous individual case safety reports (ICSRs) retrieved from the EudraVigilance database. ADRs associated with L-carnitine and CoQ10 were analyzed and compared at the System Organ Class (SOC) level. Disproportionality analyses were performed using the reporting odds ratio (ROR) and proportional reporting ratio (PRR). Results: A total of 257 ICSRs for L-carnitine and 271 for CoQ10 were identified. Serious cases accounted for 34.2% of L-carnitine reports and 74.5% of CoQ10 reports. For L-carnitine, the most frequently reported SOC categories were gastrointestinal disorders, skin and subcutaneous tissue disorders, general disorders and administration site conditions, and nervous system disorders. For CoQ10, the most commonly reported SOC categories were general disorders and administration site conditions, nervous system disorders, investigations, and gastrointestinal disorders. Comparative disproportionality analysis showed higher reporting frequencies for CoQ10 in blood and lymphatic system disorders (ROR 3.04; PRR 2.99), musculoskeletal and connective tissue disorders (ROR 2.63; PRR 2.52). Conclusions: Real-world pharmacovigilance data suggest partially different ADR reporting patterns for L-carnitine and CoQ10 compared with those described in pre-marketing studies. CoQ10 was associated with a higher proportion of serious reports and greater disproportionality signals for selected SOC categories; however, these findings should be interpreted cautiously, as reporting patterns may be influenced by reporting bias, comorbidities, concomitant therapies, and differences in the populations using these compounds. Continuous pharmacovigilance monitoring and periodic reassessment of their benefit\u2013risk profile remain essential given their widespread use in health and sports supplementation settings.<\/jats:p>","DOI":"10.3390\/nu18111716","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:36:56Z","timestamp":1779892616000},"page":"1716","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Analysis of L-Carnitine and Coenzyme Q10 Adverse Reaction Reports Using the EudraVigilance Database: Implications for Health and Sports Supplementation"],"prefix":"10.3390","volume":"18","author":[{"given":"Debora","family":"Di Mauro","sequence":"first","affiliation":[{"name":"Department of Biomedical, Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Calapai","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4075-8065","authenticated-orcid":false,"given":"Ilaria","family":"Ammendolia","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaconcetta","family":"Curr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Trimarchi","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-6284","authenticated-orcid":false,"given":"Carmen","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.numecd.2019.07.012","article-title":"Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials","volume":"29","author":"Askarpour","year":"2019","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1249\/JSR.0b013e318180735c","article-title":"L-carnitine supplementation: Influence upon physiological function","volume":"7","author":"Kraemer","year":"2008","journal-title":"Curr. Sports Med. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12970-020-0334-3","article-title":"CoQ10 status, glucose parameters, and antioxidative capacity in college athletes","volume":"17","author":"Ho","year":"2020","journal-title":"J. Int. Soc. Sports Nutr."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fernandes, M.S.S., Fidelis, D.E.D.S., Aidar, F.J., Badicu, G., Greco, G., Cataldi, S., Santos, G.C.J., de Souza, R.F., and Ardig\u00f2, L.P. (2023). CoQ10 Supplementation in Athletes: A Systematic Review. Nutrients, 15.","DOI":"10.3390\/nu15183990"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.20463\/jenb.2018.0026","article-title":"Effects of nine weeks L-Carnitine supplementation on exercise performance, anaerobic power, and exercise-induced oxidative stress in resistance-trained males","volume":"22","author":"Koozehchian","year":"2018","journal-title":"J. Exerc. Nutr. Biochem."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mielgo-Ayuso, J., Pietrantonio, L., Viribay, A., Calleja-Gonz\u00e1lez, J., Gonz\u00e1lez-Bernal, J., and Fern\u00e1ndez-L\u00e1zaro, D. (2021). Effect of Acute and Chronic Oral l-Carnitine Supplementation on Exercise Performance Based on the Exercise Intensity: A Systematic Review. Nutrients, 13.","DOI":"10.3390\/nu13124359"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vecchio, M., Chiaramonte, R., Testa, G., and Pavone, V. (2021). Clinical Effects of L-Carnitine Supplementation on Physical Performance in Healthy Subjects, the Key to Success in Rehabilitation: A Systematic Review and Meta-Analysis from the Rehabilitation Point of View. J. Funct. Morphol. Kinesiol., 6.","DOI":"10.3390\/jfmk6040093"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E474","DOI":"10.1152\/ajpendo.00277.2001","article-title":"L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress","volume":"282","author":"Volek","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Fielding, R., Riede, L., Lugo, J.P., and Bellamine, A. (2018). l-Carnitine Supplementation in Recovery after Exercise. Nutrients, 10, Erratum in Nutrients 2018, 10, 541. https:\/\/doi.org\/10.3390\/nu10050541.","DOI":"10.3390\/nu10050541"},{"key":"ref_10","unstructured":"(2026, March 20). Summary of Product Characteristics for Levocarnitine. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/15069\/smpc#gref."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12970-020-00377-2","article-title":"The bright and the dark sides of L-carnitine supplementation: A systematic review","volume":"17","author":"Sawicka","year":"2020","journal-title":"J. Int. Soc. Sports Nutr."},{"key":"ref_12","unstructured":"(2026, March 20). Summary Products Characteristics for Myoqinon. Available online: https:\/\/bpb-eu-w2.wpmucdn.com\/blogs.bristol.ac.uk\/dist\/e\/1083\/files\/2024\/06\/SmPC-Myoqinon-EN-translation.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/07315724.2001.10719063","article-title":"Biochemical functions of CoQ10","volume":"20","author":"Crane","year":"2001","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbrc.2010.02.147","article-title":"Coenzyme Q\u2014Biosynthesis and functions","volume":"396","author":"Bentinger","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clnesp.2024.01.015","article-title":"The effects of CoQ10 supplementation on biomarkers of exercise-induced muscle damage, physical performance, and oxidative stress: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials","volume":"60","author":"Talebi","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Drobnic, F., Lizarraga, M.A., Caballero-Garc\u00eda, A., and Cordova, A. (2022). CoQ10 Supplementation and Its Impact on Exercise and Sport Performance in Humans: A Recovery or a Performance-Enhancing Molecule?. Nutrients, 14.","DOI":"10.3390\/nu14091811"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bagheri, N., Kargarfard, M., Bagheri, R., and Dutheil, F. (2025). Effects of Coenzyme Q10 Supplementation on Physical Function Adaptations to High-Intensity Interval Training in Older Adults. Nutrients, 17.","DOI":"10.3390\/nu17243959"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ammendolia, I., Mannucci, C., Cardia, L., Calapai, G., Gangemi, S., Esposito, E., and Calapai, F. (2023). Pharmacovigilance on cannabidiol as an antiepileptic agent. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1091978"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sportiello, L., and Capuano, A. (2024). Sex and gender differences and pharmacovigilance: A knot still to be untied. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1397291"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Calapai, F., Ammendolia, I., Cardia, L., Curr\u00f2, M., Calapai, G., Esposito, E., and Mannucci, C. (2023). Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071933"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fusaroli, M., Salvo, F., Khouri, C., and Raschi, E. (2024). The reporting of disproportionality analysis in pharmacovigilance: Spotlight on the READUS-PV guideline. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1488725"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2024). Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Matsuda, S., Aoki, K., Kawamata, T., Kimotsuki, T., Kobayashi, T., Kuriki, H., Nakayama, T., Okugawa, S., Sugimura, Y., and Tomita, M. (2015). Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126413"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1177\/0960327115571767","article-title":"The adverse effects of long-term l-carnitine supplementation on liver and kidney function in rats","volume":"34","author":"Liu","year":"2015","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/BF01799937","article-title":"Possible deleterious effect of L-carnitine supplementation in a patient with mild multiple acyl-CoA dehydrogenation deficiency (ethylmalonic-adipic aciduria)","volume":"14","author":"Green","year":"1991","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neurol.2010.08.015","article-title":"Traitement par L-carnitine et mauvaise odeur corporelle: Un effet secondaire \u00e0 conna\u00eetre [L-carnitine treatment and fish odor syndrome: An unwaited adverse effect]","volume":"167","author":"Rocher","year":"2011","journal-title":"Rev. Neurol."},{"key":"ref_27","first-page":"e166","article-title":"Nutritional support and cardioprotection with L-carnitine: Prescription appropriateness and safety concerns in Mexican neonates","volume":"18","year":"2011","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2005.12.002","article-title":"Safety assessment of CoQ10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial","volume":"44","author":"Ikematsu","year":"2006","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.yrtph.2006.06.007","article-title":"Risk assessment for carnitine","volume":"46","author":"Hathcock","year":"2006","journal-title":"Regul. Toxicol. Pharmacol. RTP"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/biof.5520320124","article-title":"Safety assessment of CoQ10 (CoQ10)","volume":"32","author":"Hidaka","year":"2008","journal-title":"Biofactors"},{"key":"ref_31","first-page":"3226","article-title":"Interaktion mellem warfarin og coenzym Q10 [Interaction between warfarin and coenzyme Q10]","volume":"160","author":"Landbo","year":"1998","journal-title":"Ugeskr. Laeger"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/11\/1716\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:20:25Z","timestamp":1780536025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/11\/1716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["nu18111716"],"URL":"https:\/\/doi.org\/10.3390\/nu18111716","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}